Home Cart Sign in  
Chemical Structure| 14215-86-2 Chemical Structure| 14215-86-2

Structure of Sweroside
CAS No.: 14215-86-2

Chemical Structure| 14215-86-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sweroside, a natural product isolated and purified from the herbs of Swertia bimaculata with strong hepatoprotective, anti-osteoporotic, insulin-mimicking, and wound-healing effects, can inhibit potent melanogenesis in melan-a cells at 300uM without cytotoxicity, also decreases tyrosinase, tyrosinase-related protein-1 (TRP-1) and TRP-2 protein production in melan a cells.

Synonyms: 1,9-trans-9,5-cis-Sweroside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sweroside

CAS No. :14215-86-2
Formula : C16H22O9
M.W : 358.34
SMILES Code : O=C1C2=CO[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](C=C)[C@]2([H])CCO1
Synonyms :
1,9-trans-9,5-cis-Sweroside
MDL No. :MFCD09954487
InChI Key :VSJGJMKGNMDJCI-ZASXJUAOSA-N
Pubchem ID :161036

Safety of Sweroside

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SH-SY5Y cells 302.0 ng/mL 24 h To evaluate the effect of Sweroside on the expression of CREB and GAP-43. The results showed that Sweroside significantly increased the expression of CREB and GAP-43 (P<0.01). PMC6643060
Bone marrow-derived macrophages (BMDMs) 100 µM 1 h Inhibited NLRP3 inflammasome activation, reduced IL-1β secretion and caspase-1 (p20) production PMC7216241
H9c2 cardiomyoblast cells 2-20 μM 24 h To evaluate the protective effects of Sweroside on aconitine-induced toxicity in H9c2 cells. Results showed that Sweroside significantly increased cell viability, reduced LDH leakage, and inhibited aconitine-induced oxidative stress and intracellular ROS production. PMC6209819
RAW264.7 cells 20, 40, 80 μM 7 days To investigate the anti-inflammatory effect of sweroside in LPS-induced RAW264.7 cells. Results showed that sweroside significantly inhibited cell proliferation, reduced the production of NO, PGE2, and ROS, and alleviated inflammation by activating SIRT1 to suppress NF-κB and promote FOXO1 signaling pathways. PMC6429084

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 N mice TAC-induced heart failure model Intraperitoneal injection 15, 30, 60 mg/kg Once daily for 8 weeks Sweroside significantly improved cardiac function in TAC-induced mice, increased EF and FS, and reduced myocardial fibrosis and cardiomyocyte hypertrophy. PMC11219961
C57BL/6J mice ANIT-induced cholestatic liver injury model Oral 120 mg/kg Once daily for 5 consecutive days To evaluate the protective effect of Sweroside on ANIT-induced cholestatic liver injury, results showed that Sweroside attenuated liver injury by restoring bile acid synthesis and transport to normal levels and suppressing pro-inflammatory responses. PMC5022106
Zebrafish (Danio rerio) Scopolamine-induced memory deficits model Immersion 2.79, 8.35, and 13.95 nM Once daily for 8 days Sweroside significantly improved the Sco-induced decrease of the cholinergic system activity and brain oxidative stress. These results suggest that sweroside exerts a significant effect on anxiety and cognitive impairment, driven in part by the modulation of the cholinergic system activity and brain antioxidant action. PMC9502219
C57BL/6 mice Methionine-choline-deficient (MCD) diet-induced NASH model Intraperitoneal injection 5 and 30 mg/kg Once daily for two weeks Alleviated hepatic inflammation, fat accumulation, and fibrosis, suppressed hepatic NLRP3 inflammasome activation, and reduced IL-1β and caspase-1 production PMC7216241
Sprague-Dawley rats Aconitine-induced arrhythmia model Intraperitoneal injection 50 mg/kg Once daily for 5 days To evaluate the protective effects of Sweroside on aconitine-induced arrhythmias. Results showed that Sweroside significantly reduced the incidence of arrhythmias and lowered the risk of ventricular fibrillation and sudden death. PMC6209819

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.79mL

0.56mL

0.28mL

13.95mL

2.79mL

1.40mL

27.91mL

5.58mL

2.79mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories